---
aliases: [AZN]
---
#actor #pharma #oncology #uk #public

**AstraZeneca** — Oncology-focused pharma. ~$50B revenue. Tagrisso, Imfinzi, Enhertu. $80B 2030 target.

---

## Why AstraZeneca matters

| Metric | Value |
|--------|-------|
| Ticker | AZN |
| Market cap | ~$200B |
| 2025E revenue | **~$50.5B** |
| HQ | Cambridge, [[UK]] |
| 2030 target | **$80B revenue** |

---

## 2025 financial performance

| Period | Revenue | Growth |
|--------|---------|--------|
| 9M 2025 | $43.2B | +11% (CER) |
| FY25E | ~$50.5B | High single digit |
| Core EPS 9M | $7.04 | +15% |

---

## Oncology dominance

| Metric | Value |
|--------|-------|
| Oncology revenue 9M | **$18.6B** |
| % of total | ~43% |
| Growth | +16% |

### Key oncology drugs

| Drug | Indication | 2025 status |
|------|------------|-------------|
| **Tagrisso** | NSCLC | ~$7.5B, flagship |
| **Imfinzi** | Multiple cancers | Growing |
| **Lynparza** | BRCA cancers | Mature |
| **Enhertu** | HER2 cancers | Daiichi partnership |
| **Calquence** | Blood cancers | Growing |

---

## Other segments

| Area | Key drugs |
|------|-----------|
| **Cardiovascular** | Farxiga, Brilinta |
| **Respiratory** | Symbicort, Breztri |
| **Rare disease** | Expanding |

---

## Pipeline

| Metric | 2025 |
|--------|------|
| Positive Phase III trials | **16** |
| New Phase III data expected | 7 medicines |
| Key candidates | Camizestrant, Volrustomig |

---

## Investment case

**Bull:**
- Oncology growth engine (+16%)
- Tagrisso $7.5B+ franchise
- Enhertu partnership upside
- $80B 2030 ambition
- Strong pipeline execution

**Bear:**
- Tagrisso competition coming
- [[China]] investigation overhang
- [[Patent cliffs]] ahead
- Acquisition integration risk
- High expectations priced in

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | AZN |
| 2025E revenue | ~$50.5B |
| Oncology % | 43% |
| 2030 target | $80B |

---

## Related

- [[Biopharma]] — sector
- [[Eli Lilly]] — pharma peer
- [[Roche]] — oncology competitor
- [[Tempus]] — AI pharma deals ($200M)

---

## Sources

- [AstraZeneca Q3 2025](https://www.astrazeneca.com/content/dam/az/PDF/2025/9m-q3/9M-and-Q3-2025-results-announcement.pdf)
- [[[Nasdaq]] Analysis](https://www.nasdaq.com/articles/astrazeneca-rides-oncology-momentum-blockbuster-and-new-drugs)

*Created 2026-01-09*
